Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures of -$73K in Q2 FY2026
Q2 FY2026 capital expenditures was -$73K.
Context
- Capital expenditures amounted to 171.3% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.31M) USD
- Year-over-year change
- -30.5%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.31M) | -30.5% |
| FY2024 | 2024-12-31 | (1.77M) | — |
Capital Expenditures vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 capital expenditures of $2.31M is the largest of the 10 companies compared; the peer median is $81K.
- Its year-over-year change of +30.5% is the 4th highest of 9, against a peer median of -38.2%.
- Capital expenditures amounts to 171.3% of revenue for ATTO, versus a peer median of 2.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2025 | $2.31M | +30.5% | — | 171.3% | |
| FY2025 | $434K | -42.1% | -53.4% | 678.1% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $401K | -77.7% | -35.3% | 5.4% |
EVMNEvommune, Inc. | LTM Mar 2026 | $318K | — | — | 3.2% |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $219K | +33.5% | +371.0% | — |
| LTM Mar 2026 | $81K | -99.8% | -43.2% | 1.0% | |
ZURAZura Bio Limited | LTM Mar 2026 | $77K | -34.2% | -78.9% | — |
| LTM Mar 2026 | $69K | -81.1% | -37.6% | 0.0% | |
| LTM Mar 2026 | $0 | +100.0% | +29.8% | — | |
| LTM Mar 2026 | $0 | +100.0% | — | 0.0% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $81K | -38.2% | -37.6% | 2.1% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.